MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. (GOVX)

|||

Cash Flow Overview

Change in Cash
$1,871,660
Free Cash flow
-$3,658,103
Unit: Dollar
Positive Cash Flow Breakdown
    • Net proceeds from sale of common...
    • Net proceeds from warrant exerci...
    • Accounts payable and accrued exp...
    • Others
Negative Cash Flow Breakdown
    • Net loss
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-4,426,578
-5,261,921
-4,418,423
-6,318,914
Depreciation and amortization expense
12,076
12,076
18,230
16,802
Stock-based compensation expense
163,746
219,317
252,124
277,546
Government contract receivable
0
0
0
-532,771
Prepaid expenses and other current assets
-127,830
-1,072,281
674,826
-664
Other assets
-
-
-43,560
15,937
Accounts payable and accrued expenses
464,823
420,526
-182,441
-705,047
Total adjustments
768,475
1,724,200
-543,353
106,799
Net cash used in operating activities
-3,658,103
-3,537,721
-4,961,776
-6,212,115
Purchase of equipment
0
0
0
0
Net cash used in investing activities
0
0
0
0
Net proceeds from issuance of notes payable related parties
-
-
0
0
Repayment of notes payable related parties
-
-
0
0
Net proceeds from sale of common stock and warrants
3,554,080
1,718,901
3,038,520
7,971,250
Net proceeds from warrant exercises
1,975,683
4,841
0
156,000
Net cash provided by financing activities
5,529,763
1,723,742
3,038,520
8,127,250
Net increase (decrease) in cash and cash equivalents
1,871,660
-1,813,979
-1,923,256
1,915,135
Cash and cash equivalents at beginning of period
1,271,762
3,085,741
5,008,997
5,506,941
Cash and cash equivalents at end of period
3,143,422
1,271,762
3,085,741
5,008,997
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromsale of common stock...$3,554,080 (-55.09%↓ Y/Y)Net proceeds fromwarrant exercises$1,975,683 (945202.87%↑ Y/Y)Net cash provided byfinancing activities$5,529,763 (-30.13%↓ Y/Y)Accounts payable andaccrued expenses$464,823 (180.40%↑ Y/Y)Stock-based compensationexpense$163,746 (-72.03%↓ Y/Y)Prepaid expenses andother current assets-$127,830 (50.76%↑ Y/Y)Depreciation andamortization expense$12,076 (-64.19%↓ Y/Y)Net increase(decrease) in cash and cash...$1,871,660 (177.56%↑ Y/Y)Canceled cashflow$3,658,103 Total adjustments$768,475 (79.82%↑ Y/Y)Net cash used inoperating activities-$3,658,103 (64.48%↑ Y/Y)Canceled cashflow$768,475 Net loss-$4,426,578 (58.74%↑ Y/Y)